Business Context and Reporting Period
MediciNova, Inc. filed this Form 8-K on December 17, 2009, to report the completion of a merger with Avigen, Inc. On December 18, 2009, Absolute Merger, Inc., a wholly-owned subsidiary of MediciNova, merged with and into Avigen, Inc., with Avigen continuing as a wholly-owned subsidiary of MediciNova.
Key Financial Metrics and Transaction Structure
This filing details a material definitive agreement and asset acquisition rather than standard periodic financial results. Key transaction values include:
- First Payment Consideration: Approximately $1.19 per share of Avigen common stock (Total: $35,461,000).
- Second Payment Consideration: Estimated at no more than approximately $0.04 per share, derived from an escrow account.
- Escrow Account: Funded with $1,500,000 at closing. $400,000 was released immediately to satisfy identified liabilities.
- Convertible Notes: Initial principal amount of $29,445,824.82 deposited in trust. Maturity date is June 18, 2011. Initial conversion price is $6.80 per share.
- Contingent Payment Rights (CPR): Potential future payments include up to $6,000,000 based on Genzyme milestone payments, 50% of net proceeds from the sale of the Parkinson's Product within 20 months, or approximately $550,000 upon termination of a specific trust.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the current period versus the prior period. The primary material change is the acquisition of Avigen, Inc., which resulted in:
- The cancellation and extinguishment of all outstanding Avigen common stock and options.
- The creation of new secured debt obligations (Convertible Notes) and contingent liabilities (CPRs) for MediciNova.
- The establishment of a trust agreement securing the Convertible Notes.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing contains forward-looking statements regarding the Merger and future operations, noting that actual results may differ materially from projections. No specific revenue or earnings guidance is provided in this document.
Risks and Contingencies:
- Escrow Disputes: The timing of the Second Payment Consideration is subject to delay if MediciNova and the stockholder representative dispute the "Demand Amount" regarding additional liabilities. An independent accounting firm will resolve such disputes.
- Contingent Payments: Future cash outflows depend on specific milestones (Genzyme payments) or asset sales (Parkinson's Product) occurring within 20 months of the merger.
- Debt Obligations: The Convertible Notes are a secured obligation of MediciNova. The Indenture does not limit other indebtedness.
Important Facts for Investor Verification
- Verify the exact amount of the "Demand Amount" MediciNova may submit by June 30, 2010, to determine the final Second Payment Consideration.
- Monitor the status of the Genzyme Agreement milestone payments and the potential sale of the Parkinson's Product to assess CPR payout likelihood.
- Review the full text of the Indenture (Exhibit 4.1) and Escrow Agreement (Exhibit 10.1) for detailed covenants and default provisions.
- Confirm the pro forma financial impact of the merger, which was previously filed in the Form S-4 (Registration No. 333-161969).